Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Anthony Elias

Concepts (665)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
109
2025
2447
5.770
 Why?
Antineoplastic Combined Chemotherapy Protocols
96
2025
1953
3.780
 Why?
Sarcoma
33
2025
205
3.670
 Why?
Receptors, Estrogen
22
2021
457
2.200
 Why?
Triple Negative Breast Neoplasms
14
2024
215
2.170
 Why?
Hematopoietic Stem Cell Transplantation
36
2011
674
1.890
 Why?
Carcinoma, Small Cell
19
2003
173
1.650
 Why?
Soft Tissue Neoplasms
14
2022
127
1.510
 Why?
Carcinoma, Ductal, Breast
7
2018
88
1.430
 Why?
Neoadjuvant Therapy
18
2025
462
1.280
 Why?
Antineoplastic Agents
31
2023
2192
1.190
 Why?
Neoplasm Recurrence, Local
20
2022
1137
1.090
 Why?
Neoplasm Staging
36
2025
1461
1.050
 Why?
Receptors, Progesterone
13
2020
356
1.010
 Why?
Combined Modality Therapy
52
2024
1264
0.970
 Why?
Lung Neoplasms
38
2003
2637
0.970
 Why?
Doxorubicin
24
2025
397
0.940
 Why?
Biomarkers, Tumor
17
2022
1313
0.930
 Why?
Paclitaxel
14
2024
255
0.870
 Why?
Bone Marrow Transplantation
27
1998
294
0.870
 Why?
CTLA-4 Antigen
1
2025
104
0.870
 Why?
Mastectomy
9
2018
162
0.860
 Why?
Bone Neoplasms
7
2025
253
0.820
 Why?
Antibodies, Monoclonal, Humanized
10
2025
985
0.770
 Why?
Antineoplastic Agents, Alkylating
5
2018
72
0.720
 Why?
Receptors, Androgen
7
2018
153
0.700
 Why?
Female
169
2025
77976
0.700
 Why?
Disease-Free Survival
24
2023
768
0.680
 Why?
Humans
227
2025
144261
0.670
 Why?
Middle Aged
112
2025
35762
0.640
 Why?
Maytansine
3
2021
18
0.630
 Why?
Antineoplastic Agents, Hormonal
10
2018
194
0.630
 Why?
Liposarcoma
4
2023
31
0.630
 Why?
Neoplasm Metastasis
23
2024
688
0.570
 Why?
Adult
114
2025
40262
0.560
 Why?
Chemotherapy, Adjuvant
23
2023
419
0.560
 Why?
Dioxoles
2
2015
9
0.540
 Why?
Tetrahydroisoquinolines
2
2015
8
0.540
 Why?
Cyclophosphamide
31
2024
266
0.540
 Why?
Androgen Receptor Antagonists
6
2021
35
0.500
 Why?
Ifosfamide
19
1998
38
0.500
 Why?
Phenylthiohydantoin
5
2017
44
0.490
 Why?
Aged
65
2025
25850
0.490
 Why?
Dasatinib
1
2016
57
0.480
 Why?
Trastuzumab
10
2024
118
0.460
 Why?
Neoplasms, Hormone-Dependent
3
2012
41
0.460
 Why?
Treatment Outcome
43
2024
11643
0.440
 Why?
Drug Administration Schedule
24
2018
778
0.430
 Why?
Carboplatin
21
2016
160
0.430
 Why?
Estrogen Receptor alpha
5
2021
161
0.420
 Why?
Granulocyte Colony-Stimulating Factor
11
2002
89
0.420
 Why?
Carcinoma, Non-Small-Cell Lung
17
2001
1180
0.400
 Why?
Clinical Trials as Topic
19
2018
1050
0.400
 Why?
Estrogens
6
2018
380
0.390
 Why?
Dacarbazine
9
2018
100
0.370
 Why?
Tamoxifen
9
2018
217
0.350
 Why?
Survival Rate
19
2021
2088
0.350
 Why?
Survival Analysis
23
2010
1382
0.340
 Why?
Neoplasms
20
2009
2870
0.340
 Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2013
981
0.340
 Why?
Prognosis
22
2021
4278
0.330
 Why?
Venous Thromboembolism
3
2020
324
0.330
 Why?
Programmed Cell Death 1 Receptor
2
2025
264
0.330
 Why?
Pyrimidines
3
2020
532
0.330
 Why?
Neoplasms, Second Primary
3
2022
100
0.330
 Why?
Dose-Response Relationship, Drug
17
2017
2026
0.320
 Why?
Carcinoma, Intraductal, Noninfiltrating
3
2022
61
0.320
 Why?
Antibodies, Monoclonal
9
2024
1519
0.310
 Why?
Taxoids
7
2023
116
0.310
 Why?
Remission Induction
16
2002
306
0.310
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
8
1999
161
0.310
 Why?
Breast Neoplasms, Male
3
2018
29
0.310
 Why?
Drug Resistance, Neoplasm
7
2017
881
0.290
 Why?
Gene Expression Regulation, Neoplastic
11
2018
1455
0.280
 Why?
Neoplastic Cells, Circulating
2
2020
81
0.280
 Why?
Mesna
12
1998
16
0.270
 Why?
Sarcoma, Ewing
3
2022
102
0.260
 Why?
Leiomyosarcoma
2
2018
28
0.260
 Why?
Cisplatin
14
2000
334
0.250
 Why?
Sternum
1
2006
26
0.250
 Why?
Immunoconjugates
3
2024
132
0.250
 Why?
Immunohistochemistry
5
2016
1715
0.240
 Why?
Tumor Microenvironment
4
2024
732
0.230
 Why?
Mastectomy, Segmental
2
2009
108
0.230
 Why?
Chondrosarcoma
1
2025
17
0.230
 Why?
Carcinoma, Ductal
1
2005
10
0.220
 Why?
Peripheral Blood Stem Cell Transplantation
2
2002
35
0.220
 Why?
Melphalan
10
2002
42
0.220
 Why?
Isocitrate Dehydrogenase
1
2025
70
0.220
 Why?
Transplantation, Autologous
19
2002
290
0.220
 Why?
Pyridines
2
2025
605
0.220
 Why?
Cell Adhesion Molecules
2
2021
177
0.220
 Why?
Carcinoma
2
2008
227
0.220
 Why?
Male
66
2025
72035
0.210
 Why?
Lymph Nodes
1
2007
502
0.210
 Why?
Protein Kinase Inhibitors
4
2019
968
0.210
 Why?
Drug Evaluation
19
1998
79
0.210
 Why?
Risk Reduction Behavior
2
2016
225
0.210
 Why?
Glycine
1
2025
187
0.210
 Why?
Adjuvants, Immunologic
3
2022
245
0.200
 Why?
Ribonuclease III
2
2016
44
0.200
 Why?
Deoxycytidine
4
2020
221
0.200
 Why?
Ovarian Neoplasms
3
2022
586
0.200
 Why?
Survivors
3
2016
516
0.200
 Why?
Thiotepa
13
2002
21
0.200
 Why?
Alkylating Agents
3
2000
24
0.200
 Why?
Hodgkin Disease
4
2016
171
0.200
 Why?
DEAD-box RNA Helicases
2
2016
90
0.190
 Why?
Triazoles
2
2022
184
0.190
 Why?
Weight Loss
4
2016
832
0.190
 Why?
Behavior Therapy
2
2016
281
0.190
 Why?
Gene Expression Profiling
6
2017
1782
0.190
 Why?
Aged, 80 and over
14
2021
8243
0.190
 Why?
Disease Management
5
2020
643
0.190
 Why?
Employment
1
2024
185
0.180
 Why?
Mutation
4
2025
4085
0.180
 Why?
Obesity
4
2018
3057
0.180
 Why?
Medical Oncology
5
2024
331
0.180
 Why?
Hydrazines
1
2022
37
0.180
 Why?
Salvage Therapy
6
2010
162
0.180
 Why?
Overweight
3
2016
606
0.180
 Why?
Carcinoma in Situ
2
2012
44
0.180
 Why?
Circulating Tumor DNA
1
2022
43
0.180
 Why?
Etoposide
10
2001
166
0.180
 Why?
Tumor Cells, Cultured
9
2020
919
0.170
 Why?
Hematologic Diseases
6
2008
66
0.170
 Why?
Sarcoma, Synovial
1
2021
20
0.170
 Why?
Liposarcoma, Myxoid
1
2021
10
0.170
 Why?
Emergency Medicine
1
2024
261
0.170
 Why?
Referral and Consultation
1
2007
847
0.170
 Why?
Recombinant Fusion Proteins
1
2024
674
0.170
 Why?
Endpoint Determination
1
2021
83
0.160
 Why?
Aromatase Inhibitors
4
2021
75
0.160
 Why?
Sentinel Lymph Node Biopsy
3
2017
118
0.160
 Why?
Leukocytes, Mononuclear
3
2020
573
0.160
 Why?
Indazoles
1
2020
80
0.160
 Why?
Cell Separation
3
2017
307
0.160
 Why?
Hematopoietic Stem Cells
5
1996
420
0.160
 Why?
Cancer Care Facilities
1
2020
48
0.160
 Why?
Antigens, Neoplasm
4
2021
271
0.160
 Why?
Time Factors
12
2020
7155
0.160
 Why?
Diphosphonates
1
2020
68
0.150
 Why?
Diet
3
2018
1271
0.150
 Why?
Pyrroles
2
2013
217
0.150
 Why?
Bone Marrow
8
2000
304
0.150
 Why?
Nuclear Medicine
1
2019
9
0.150
 Why?
Hematology
1
2019
21
0.150
 Why?
Bridged-Ring Compounds
4
2023
31
0.150
 Why?
Cell Line, Tumor
9
2017
3539
0.140
 Why?
MCF-7 Cells
5
2017
135
0.140
 Why?
Proportional Hazards Models
6
2020
1322
0.140
 Why?
CA-125 Antigen
2
2013
13
0.140
 Why?
Fluorouracil
7
2013
235
0.140
 Why?
Pyrazoles
2
2022
509
0.140
 Why?
Epithelial-Mesenchymal Transition
1
2020
219
0.140
 Why?
Pulmonary Medicine
1
2019
79
0.140
 Why?
Thromboembolism
1
2019
125
0.140
 Why?
Benzamides
5
2017
224
0.140
 Why?
Bayes Theorem
4
2024
433
0.140
 Why?
Research Design
3
2021
1129
0.140
 Why?
Receptor, Fibroblast Growth Factor, Type 1
1
2018
58
0.140
 Why?
Nitriles
5
2017
205
0.130
 Why?
Tissue Inhibitor of Metalloproteinase-3
1
2017
9
0.130
 Why?
Cyclin-Dependent Kinase 4
1
2018
53
0.130
 Why?
Cell Cycle
1
2021
596
0.130
 Why?
Infusions, Intravenous
10
2020
423
0.130
 Why?
Cyclin-Dependent Kinase 6
1
2018
49
0.130
 Why?
Kaplan-Meier Estimate
6
2018
964
0.130
 Why?
Schwann Cells
1
2017
33
0.130
 Why?
Tetrahydronaphthalenes
1
2017
31
0.130
 Why?
Sciatic Nerve
1
2017
59
0.130
 Why?
Vaccines
1
2022
389
0.130
 Why?
Microbubbles
1
2017
53
0.130
 Why?
Valine
1
2017
80
0.130
 Why?
Venous Thrombosis
1
2019
194
0.130
 Why?
Betacoronavirus
1
2020
285
0.130
 Why?
Amyloid Precursor Protein Secretases
1
2017
77
0.130
 Why?
Societies, Medical
2
2019
886
0.130
 Why?
Lymph Node Excision
3
2015
173
0.130
 Why?
Indoles
2
2013
501
0.130
 Why?
Camptothecin
3
2024
140
0.130
 Why?
Axilla
3
2017
51
0.130
 Why?
Sulfonamides
1
2020
580
0.120
 Why?
Androgen Antagonists
2
2015
91
0.120
 Why?
Immunotherapy
2
2018
652
0.120
 Why?
Cancer-Associated Fibroblasts
1
2016
23
0.120
 Why?
Gonadal Steroid Hormones
1
2018
144
0.120
 Why?
Hematopoietic Cell Growth Factors
2
1995
5
0.120
 Why?
Neoplasms, Germ Cell and Embryonal
2
1995
75
0.120
 Why?
Ultrasonography, Mammary
1
2016
15
0.120
 Why?
Neoplasms, Radiation-Induced
1
2016
99
0.120
 Why?
Antibody Specificity
1
2016
181
0.120
 Why?
Lymphatic Metastasis
3
2017
333
0.120
 Why?
Thiazoles
1
2016
135
0.120
 Why?
Internship and Residency
2
2024
1255
0.120
 Why?
Anesthesiology
1
2019
175
0.120
 Why?
Tumor Suppressor Protein p53
2
2023
529
0.120
 Why?
Follow-Up Studies
6
2025
5389
0.120
 Why?
Neoplasm Invasiveness
3
2016
508
0.120
 Why?
Myelin Sheath
1
2017
168
0.120
 Why?
Maximum Tolerated Dose
1
2016
212
0.120
 Why?
Neoplastic Stem Cells
2
2017
412
0.110
 Why?
Antibiotics, Antineoplastic
1
2016
139
0.110
 Why?
Ambulatory Care
1
2020
597
0.110
 Why?
Benzimidazoles
1
2016
190
0.110
 Why?
Quinolines
1
2016
190
0.110
 Why?
Pneumonia, Viral
1
2020
382
0.110
 Why?
Coronavirus Infections
1
2020
377
0.110
 Why?
Drug Therapy, Combination
4
2014
1044
0.110
 Why?
Recurrence
5
2020
1134
0.110
 Why?
Mammography
1
2016
165
0.110
 Why?
Animals
17
2021
38030
0.110
 Why?
Disease Progression
7
2018
2840
0.110
 Why?
Radiotherapy, Adjuvant
5
2016
222
0.110
 Why?
Homeodomain Proteins
2
2018
523
0.100
 Why?
Brain Edema
1
2014
62
0.100
 Why?
Administration, Oral
4
2020
847
0.100
 Why?
Hepatic Veno-Occlusive Disease
3
2002
12
0.100
 Why?
Antibodies
1
2016
401
0.100
 Why?
Radiotherapy Dosage
3
1999
289
0.100
 Why?
Young Adult
10
2025
13990
0.100
 Why?
TOR Serine-Threonine Kinases
1
2017
449
0.100
 Why?
Vascular Neoplasms
1
2013
18
0.100
 Why?
Clinical Trials, Phase I as Topic
3
2024
52
0.100
 Why?
Comorbidity
5
2017
1646
0.100
 Why?
Testicular Neoplasms
1
1995
113
0.100
 Why?
Radiotherapy
3
2015
206
0.100
 Why?
Exercise
2
2015
2193
0.100
 Why?
Apoptosis
6
2023
2430
0.100
 Why?
Keratins
2
2017
172
0.100
 Why?
Epigenesis, Genetic
2
2018
684
0.100
 Why?
Mercaptoethanol
2
1990
9
0.100
 Why?
Cellular Reprogramming
1
2014
103
0.100
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
3
2022
132
0.100
 Why?
Adenocarcinoma
6
2015
927
0.100
 Why?
Mice
12
2021
18329
0.100
 Why?
Cell Proliferation
6
2017
2494
0.090
 Why?
Gallium Radioisotopes
1
1992
15
0.090
 Why?
Patient Selection
4
2016
719
0.090
 Why?
Bone Marrow Cells
4
2000
320
0.090
 Why?
Carmustine
10
2001
52
0.090
 Why?
Protein-Tyrosine Kinases
2
2022
433
0.090
 Why?
Chromatin
1
2016
561
0.090
 Why?
Anthracyclines
3
2023
47
0.090
 Why?
Adolescent
23
2025
22281
0.090
 Why?
Methotrexate
4
2002
240
0.090
 Why?
Lymphoma, Non-Hodgkin
3
2001
124
0.090
 Why?
Brain Neoplasms
5
2014
1318
0.090
 Why?
Neoplasm, Residual
2
2022
139
0.080
 Why?
Weight Reduction Programs
1
2012
135
0.080
 Why?
Retrospective Studies
12
2023
17009
0.080
 Why?
RNA, Catalytic
1
2012
189
0.080
 Why?
Polydeoxyribonucleotides
2
2002
14
0.080
 Why?
Risk Assessment
3
2020
3637
0.080
 Why?
Age Factors
5
2019
3313
0.080
 Why?
Multivariate Analysis
4
2013
1533
0.080
 Why?
Neoplasm Grading
3
2017
307
0.080
 Why?
Neutropenia
5
2013
155
0.080
 Why?
Aorta
1
2013
429
0.080
 Why?
Leukapheresis
4
2001
27
0.080
 Why?
Carcinoma, Lobular
1
2011
56
0.080
 Why?
Radiosurgery
1
2014
400
0.080
 Why?
Biopsy
3
2018
1075
0.080
 Why?
Keratin-5
1
2010
48
0.080
 Why?
Angiogenesis Inhibitors
1
2012
236
0.080
 Why?
Liver Neoplasms
3
2015
780
0.080
 Why?
Peptide Mapping
1
2010
63
0.080
 Why?
Molecular Targeted Therapy
3
2018
431
0.080
 Why?
Electrophoresis, Gel, Two-Dimensional
1
2010
110
0.080
 Why?
Practice Patterns, Physicians'
1
2019
1347
0.080
 Why?
Piperazines
2
2023
380
0.080
 Why?
Databases, Protein
1
2010
90
0.080
 Why?
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
1
2010
143
0.080
 Why?
Urinary Tract
1
1990
48
0.070
 Why?
Benzenesulfonates
1
2009
21
0.070
 Why?
CD146 Antigen
2
2021
40
0.070
 Why?
Postmenopause
2
2017
391
0.070
 Why?
BRCA2 Protein
1
2009
67
0.070
 Why?
Health Facilities
1
2009
85
0.070
 Why?
Pregnancy Complications, Neoplastic
1
2009
63
0.070
 Why?
Observer Variation
1
2010
354
0.070
 Why?
Thrombophilia
1
2009
88
0.070
 Why?
Patient Care
1
2009
118
0.070
 Why?
Risk Factors
8
2020
10699
0.070
 Why?
Mice, Nude
3
2017
682
0.070
 Why?
Perimenopause
1
2008
66
0.070
 Why?
United States
9
2023
15876
0.070
 Why?
Fibrinolytic Agents
2
2002
291
0.070
 Why?
Bone Marrow Diseases
4
2000
20
0.070
 Why?
In Situ Hybridization
2
2010
319
0.070
 Why?
In Situ Hybridization, Fluorescence
1
2008
322
0.070
 Why?
Blotting, Western
1
2010
1187
0.060
 Why?
Fatigue
3
2018
361
0.060
 Why?
Xenograft Model Antitumor Assays
3
2017
928
0.060
 Why?
Randomized Controlled Trials as Topic
6
2000
1705
0.060
 Why?
Sputum
1
1988
308
0.060
 Why?
Pneumonectomy
3
1997
169
0.060
 Why?
Reproducibility of Results
2
2016
3403
0.060
 Why?
Proto-Oncogene Proteins c-akt
2
2019
436
0.060
 Why?
Quality of Life
2
2015
3166
0.060
 Why?
Neoplasm Proteins
2
2007
442
0.060
 Why?
Clinical Decision-Making
2
2020
358
0.060
 Why?
Life Tables
2
2002
21
0.060
 Why?
Anilides
2
2016
84
0.050
 Why?
New Jersey
1
2024
16
0.050
 Why?
Positron-Emission Tomography
1
2006
323
0.050
 Why?
Colony-Stimulating Factors
3
1988
37
0.050
 Why?
Enzyme Inhibitors
1
2008
824
0.050
 Why?
Predictive Value of Tests
2
2016
2111
0.050
 Why?
Receptor, TIE-2
1
2024
11
0.050
 Why?
New York
1
2024
124
0.050
 Why?
Granulocytes
4
1995
80
0.050
 Why?
Oligonucleotide Array Sequence Analysis
3
2012
758
0.050
 Why?
MicroRNAs
1
2010
700
0.050
 Why?
Ricin
2
1997
8
0.050
 Why?
Growth Substances
3
1988
140
0.050
 Why?
Genes, Neoplasm
1
2004
25
0.050
 Why?
Forecasting
3
2000
388
0.050
 Why?
Mammaplasty
2
2016
104
0.050
 Why?
Thrombocytopenia
3
2013
205
0.050
 Why?
Anticoagulants
2
2019
721
0.050
 Why?
Up-Regulation
2
2017
851
0.050
 Why?
Patient Care Planning
1
2005
169
0.050
 Why?
Activating Transcription Factor 4
1
2023
22
0.050
 Why?
Proteasome Inhibitors
1
2023
40
0.050
 Why?
Signal Transduction
5
2018
5221
0.050
 Why?
Magnetic Resonance Imaging
1
2016
3857
0.050
 Why?
Proto-Oncogene Proteins c-mdm2
1
2023
66
0.050
 Why?
G(M2) Ganglioside
1
2022
1
0.050
 Why?
Injection Site Reaction
1
2022
3
0.050
 Why?
Cyclin E
1
2022
23
0.050
 Why?
Clinical Trials, Phase III as Topic
2
2000
117
0.050
 Why?
Proteomics
1
2010
1191
0.050
 Why?
Treatment Failure
2
2001
363
0.050
 Why?
Luminescent Measurements
1
2003
76
0.050
 Why?
France
2
2019
40
0.050
 Why?
Ribose
1
2022
22
0.050
 Why?
Oncogene Proteins
1
2022
61
0.050
 Why?
Blood Transfusion, Autologous
2
1993
19
0.050
 Why?
Heterocyclic Compounds, 4 or More Rings
1
2022
23
0.050
 Why?
Carbolines
1
2022
35
0.050
 Why?
Transcriptome
2
2023
1044
0.050
 Why?
Proteasome Endopeptidase Complex
1
2023
159
0.050
 Why?
Adenosine Diphosphate
1
2022
84
0.050
 Why?
Career Choice
1
2024
236
0.050
 Why?
Imidazoles
1
2023
254
0.040
 Why?
Pyrimidinones
1
2022
126
0.040
 Why?
Class I Phosphatidylinositol 3-Kinases
1
2022
108
0.040
 Why?
Actuarial Analysis
2
1993
21
0.040
 Why?
Oncogenes
1
2022
119
0.040
 Why?
Cell Division
2
2001
766
0.040
 Why?
Gene Expression
2
2020
1487
0.040
 Why?
Colony-Forming Units Assay
4
1996
95
0.040
 Why?
Tomography, X-Ray Computed
2
2015
2730
0.040
 Why?
Carcinoembryonic Antigen
1
2001
38
0.040
 Why?
Phthalazines
1
2021
64
0.040
 Why?
Transplantation Immunology
1
2000
29
0.040
 Why?
Clodronic Acid
1
2020
19
0.040
 Why?
Prospective Studies
5
2022
7970
0.040
 Why?
Fellowships and Scholarships
1
2024
355
0.040
 Why?
Longitudinal Studies
2
2012
2926
0.040
 Why?
Ligands
1
2022
673
0.040
 Why?
Progesterone
1
2002
255
0.040
 Why?
Extracellular Matrix
1
2024
553
0.040
 Why?
Phosphatidylinositol 3-Kinases
1
2022
379
0.040
 Why?
Estradiol
2
2016
533
0.040
 Why?
Topoisomerase I Inhibitors
1
1999
19
0.040
 Why?
Thoracotomy
2
1997
83
0.040
 Why?
Polymerase Chain Reaction
1
2003
1054
0.040
 Why?
Hematopoietic Stem Cell Mobilization
1
1999
27
0.040
 Why?
Leucovorin
2
1997
101
0.040
 Why?
Bone Density Conservation Agents
1
2020
81
0.040
 Why?
Mechlorethamine
1
2000
53
0.040
 Why?
Dendritic Cells
2
2000
499
0.040
 Why?
Drug Resistance
1
1999
153
0.040
 Why?
Myelodysplastic Syndromes
1
2001
147
0.040
 Why?
Neoplasms, Experimental
1
2000
173
0.040
 Why?
Receptors, Steroid
1
2019
45
0.040
 Why?
Heterocyclic Compounds, 3-Ring
1
2019
43
0.040
 Why?
Cluster Analysis
2
2012
519
0.040
 Why?
Etanidazole
1
1998
1
0.040
 Why?
Cell Cycle Proteins
1
2022
628
0.040
 Why?
Child
8
2022
22537
0.040
 Why?
Enterocolitis, Pseudomembranous
1
1998
28
0.040
 Why?
Leukemia
1
2001
245
0.040
 Why?
Expectorants
1
1998
23
0.030
 Why?
Loss of Function Mutation
1
2018
46
0.030
 Why?
Aurora Kinase A
1
2018
62
0.030
 Why?
Nervous System
2
1997
70
0.030
 Why?
Cross-Over Studies
1
2020
600
0.030
 Why?
Disease Susceptibility
1
2020
346
0.030
 Why?
Statistics, Nonparametric
1
1999
427
0.030
 Why?
Retreatment
1
2018
77
0.030
 Why?
Mediastinum
1
1998
23
0.030
 Why?
Nausea
1
2018
111
0.030
 Why?
Epithelial Cell Adhesion Molecule
1
2017
10
0.030
 Why?
Myelin Basic Protein
1
2017
44
0.030
 Why?
ADAM17 Protein
1
2017
42
0.030
 Why?
Administration, Intravenous
1
2018
170
0.030
 Why?
Bromodeoxyuridine
1
2017
79
0.030
 Why?
Extremities
2
1989
140
0.030
 Why?
Breast
1
2018
157
0.030
 Why?
SEER Program
1
2018
224
0.030
 Why?
Watchful Waiting
1
2018
88
0.030
 Why?
Diarrhea
1
2018
192
0.030
 Why?
Cell Hypoxia
1
1998
247
0.030
 Why?
Ganglia, Spinal
1
2017
88
0.030
 Why?
Double-Blind Method
1
2022
2025
0.030
 Why?
Medicare
1
2023
881
0.030
 Why?
Thorax
1
1997
50
0.030
 Why?
Coculture Techniques
1
2017
246
0.030
 Why?
Random Allocation
2
1988
363
0.030
 Why?
Phosphoramide Mustards
1
2016
4
0.030
 Why?
Heterografts
1
2017
143
0.030
 Why?
Everolimus
1
2017
111
0.030
 Why?
Immunotoxins
1
1997
55
0.030
 Why?
Cyclohexanes
1
2016
23
0.030
 Why?
Cohort Studies
4
2001
5935
0.030
 Why?
Cells, Cultured
2
2017
4146
0.030
 Why?
Cell Survival
1
2000
1098
0.030
 Why?
Cytochrome P-450 CYP3A
1
2017
93
0.030
 Why?
Placebos
1
2016
192
0.030
 Why?
Fluorescence Resonance Energy Transfer
1
2017
178
0.030
 Why?
Gene Knockdown Techniques
1
2017
336
0.030
 Why?
Ascorbic Acid
1
2017
179
0.030
 Why?
Injections, Intravenous
2
1993
200
0.030
 Why?
Carcinogenesis
1
2018
229
0.030
 Why?
Antineoplastic Agents, Immunological
1
2018
199
0.030
 Why?
Fertility Preservation
1
2016
53
0.030
 Why?
Blood Specimen Collection
1
1995
38
0.030
 Why?
Organoplatinum Compounds
3
1990
66
0.030
 Why?
Antidotes
1
1997
145
0.030
 Why?
Lymphoma, Large B-Cell, Diffuse
1
1998
192
0.030
 Why?
Digestive System
1
1995
28
0.030
 Why?
Transcriptional Activation
1
2017
382
0.030
 Why?
Genetic Therapy
1
1997
313
0.030
 Why?
Blood Component Transfusion
2
1994
103
0.030
 Why?
Animals, Newborn
1
2017
901
0.030
 Why?
Mortality
1
1997
371
0.030
 Why?
Vincristine
1
1995
140
0.030
 Why?
Hormones
1
2015
134
0.030
 Why?
Interleukin-3
1
1994
23
0.030
 Why?
Fertility
1
2016
168
0.030
 Why?
Diagnosis, Differential
1
2019
1487
0.030
 Why?
Kidney
2
1995
1495
0.030
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2017
257
0.030
 Why?
Weight Gain
1
2018
556
0.030
 Why?
Leukocyte Count
5
1996
316
0.030
 Why?
Bacterial Infections
1
1996
246
0.030
 Why?
Pulmonary Fibrosis
3
1993
395
0.030
 Why?
Odds Ratio
1
2017
1072
0.030
 Why?
Tosyl Compounds
1
2014
16
0.030
 Why?
Antioxidants
1
2017
549
0.030
 Why?
Child, Preschool
6
2013
11774
0.030
 Why?
Drug Discovery
1
2015
154
0.030
 Why?
Hand-Foot Syndrome
1
2013
2
0.030
 Why?
Adipose Tissue
1
2018
651
0.030
 Why?
Protein Transport
1
2015
441
0.030
 Why?
HEK293 Cells
1
2016
744
0.020
 Why?
Capecitabine
1
2013
57
0.020
 Why?
Transplantation, Heterologous
1
2014
193
0.020
 Why?
Neoplasm Transplantation
1
2014
251
0.020
 Why?
Necrosis
1
2014
244
0.020
 Why?
Erythropoietin
1
1994
100
0.020
 Why?
Cell Nucleus
1
2016
618
0.020
 Why?
Binding Sites
1
2016
1327
0.020
 Why?
Gene Silencing
1
2014
205
0.020
 Why?
Alternative Splicing
1
2015
247
0.020
 Why?
Blood Cells
1
1993
37
0.020
 Why?
Nutritional Status
1
2015
354
0.020
 Why?
CD24 Antigen
1
2012
18
0.020
 Why?
Recombinant Proteins
5
1997
1367
0.020
 Why?
Cross-Sectional Studies
1
2024
5813
0.020
 Why?
Sensitivity and Specificity
2
2000
1983
0.020
 Why?
Anemia
1
1994
187
0.020
 Why?
Radionuclide Imaging
1
1992
112
0.020
 Why?
Diet, Reducing
1
2012
91
0.020
 Why?
Energy Intake
1
2015
499
0.020
 Why?
Antigens, CD34
3
1996
88
0.020
 Why?
Hyaluronan Receptors
1
2012
102
0.020
 Why?
Psychotherapy, Group
1
2012
80
0.020
 Why?
Counseling
1
2015
400
0.020
 Why?
Models, Biological
1
1999
1820
0.020
 Why?
Emergency Medical Services
1
2019
696
0.020
 Why?
Vascular Endothelial Growth Factor Receptor-1
1
2012
74
0.020
 Why?
Mice, SCID
1
2012
369
0.020
 Why?
Surveys and Questionnaires
1
2024
6021
0.020
 Why?
Pandemics
1
2020
1682
0.020
 Why?
Feasibility Studies
4
1998
1087
0.020
 Why?
Tumor Burden
1
2012
319
0.020
 Why?
Fluorescent Antibody Technique
2
1990
370
0.020
 Why?
Logistic Models
1
2016
2104
0.020
 Why?
Biopsy, Needle
1
2011
183
0.020
 Why?
Mice, Inbred NOD
1
2012
610
0.020
 Why?
Chromosomes, Human, Pair 9
1
1990
36
0.020
 Why?
Blast Crisis
1
1990
35
0.020
 Why?
Immunoblotting
1
2010
300
0.020
 Why?
Colorado
1
2020
4562
0.020
 Why?
Chromosomes, Human, Pair 22
1
1990
46
0.020
 Why?
Bilirubin
2
2002
97
0.020
 Why?
Disease Models, Animal
1
2021
4556
0.020
 Why?
Graft Survival
1
1993
526
0.020
 Why?
Pemetrexed
1
2010
38
0.020
 Why?
Cytokines
1
1998
2061
0.020
 Why?
Glutamates
1
2010
66
0.020
 Why?
Antibodies, Anti-Idiotypic
1
1990
51
0.020
 Why?
Magnetics
1
1990
48
0.020
 Why?
Health Status
1
2015
833
0.020
 Why?
Urologic Diseases
1
1990
40
0.020
 Why?
Multiple Organ Failure
2
2002
124
0.020
 Why?
Real-Time Polymerase Chain Reaction
1
2010
341
0.020
 Why?
Gene Regulatory Networks
1
2012
318
0.020
 Why?
Guanine
1
2010
87
0.020
 Why?
Kidney Diseases
2
1991
425
0.020
 Why?
Hypertension
1
2018
1254
0.020
 Why?
Health Behavior
1
2015
782
0.020
 Why?
Microspheres
1
1990
142
0.020
 Why?
Chromosome Aberrations
1
1990
162
0.020
 Why?
Spinal Cord Neoplasms
1
1989
40
0.020
 Why?
Blood
1
1990
109
0.020
 Why?
RNA, Messenger
1
2017
2829
0.020
 Why?
Clone Cells
1
1990
266
0.020
 Why?
Cell Movement
1
2014
965
0.020
 Why?
Pregnancy Trimester, Second
1
2009
82
0.020
 Why?
Promoter Regions, Genetic
1
2014
1255
0.020
 Why?
Central Nervous System Diseases
1
1990
74
0.020
 Why?
Hematuria
1
1989
11
0.020
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
1990
127
0.020
 Why?
Vinblastine
2
2001
75
0.020
 Why?
Creatinine
1
1991
505
0.020
 Why?
Lymphoma
1
1990
232
0.020
 Why?
Rats
1
2017
5592
0.020
 Why?
False Negative Reactions
1
1988
60
0.020
 Why?
Pregnancy Trimester, First
1
2009
135
0.020
 Why?
DNA Methylation
1
2014
681
0.020
 Why?
Leukopenia
1
1988
33
0.020
 Why?
Immunophenotyping
2
2000
322
0.020
 Why?
Niacinamide
1
2009
86
0.020
 Why?
Apoptosis Regulatory Proteins
1
2009
186
0.020
 Why?
False Positive Reactions
1
1988
121
0.020
 Why?
Hospitals, Veterans
1
2009
259
0.020
 Why?
Drug Interactions
1
1990
397
0.020
 Why?
Phenylurea Compounds
1
2009
112
0.020
 Why?
Electrophoresis
1
1988
31
0.020
 Why?
Antigens, Differentiation
1
1988
77
0.020
 Why?
Transfection
1
2010
938
0.020
 Why?
Histones
1
2014
668
0.020
 Why?
Neurons
1
2017
1640
0.020
 Why?
Perilipin-1
1
2008
17
0.020
 Why?
Estrogen Receptor Modulators
1
2008
17
0.020
 Why?
Gene Expression Regulation
1
2017
2603
0.020
 Why?
S100 Proteins
1
2008
36
0.020
 Why?
Macrophages
2
1995
1510
0.020
 Why?
Staining and Labeling
1
1988
150
0.020
 Why?
Antigens, Surface
1
1988
157
0.020
 Why?
Vimentin
1
1988
54
0.020
 Why?
Exercise Therapy
1
2012
467
0.020
 Why?
Androstadienes
1
2008
76
0.020
 Why?
Nervous System Diseases
1
1991
282
0.020
 Why?
Community Health Services
1
2009
232
0.020
 Why?
Central Nervous System
1
1990
281
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2359
0.020
 Why?
Sarcoma, Kaposi
1
1988
83
0.020
 Why?
Bone Marrow Purging
2
1996
3
0.020
 Why?
Clinical Trials, Phase II as Topic
2
2000
77
0.020
 Why?
Lung Diseases
2
1992
787
0.020
 Why?
Biomarkers
1
2018
4254
0.020
 Why?
Health Knowledge, Attitudes, Practice
1
2015
1409
0.020
 Why?
Academic Medical Centers
1
2009
545
0.020
 Why?
Risk
2
2000
909
0.020
 Why?
Heart Diseases
1
1990
349
0.020
 Why?
Gastrointestinal Diseases
1
2008
216
0.010
 Why?
Stem Cell Transplantation
1
2007
191
0.010
 Why?
Phosphoproteins
1
2008
343
0.010
 Why?
Immunoglobulin G
1
1990
893
0.010
 Why?
Bevacizumab
1
2006
167
0.010
 Why?
Quality of Health Care
1
2009
688
0.010
 Why?
Melanoma
2
1988
760
0.010
 Why?
Body Mass Index
1
2012
2420
0.010
 Why?
Carrier Proteins
1
2008
736
0.010
 Why?
Ascites
1
2002
49
0.010
 Why?
Phenotype
1
2010
3157
0.010
 Why?
Brain
1
2014
2930
0.010
 Why?
Carcinoma, Lewis Lung
1
2001
16
0.010
 Why?
Carcinoma, Large Cell
1
2001
17
0.010
 Why?
Transplantation Conditioning
1
2002
186
0.010
 Why?
Phytohemagglutinins
1
2000
29
0.010
 Why?
CD4-CD8 Ratio
1
2000
23
0.010
 Why?
Lymphocyte Culture Test, Mixed
1
2000
51
0.010
 Why?
Hypersensitivity, Delayed
1
2000
29
0.010
 Why?
Drug Synergism
1
2001
357
0.010
 Why?
Hemorrhage
2
1998
809
0.010
 Why?
Microcomputers
1
2000
18
0.010
 Why?
Skin Tests
1
2000
94
0.010
 Why?
Louisiana
1
2000
26
0.010
 Why?
Graft vs Host Disease
1
2002
264
0.010
 Why?
Philadelphia
1
2000
55
0.010
 Why?
Immunoglobulins
1
2000
160
0.010
 Why?
Automation
1
2000
102
0.010
 Why?
Immunity
1
2000
139
0.010
 Why?
Lipopolysaccharide Receptors
1
1999
87
0.010
 Why?
Marriage
1
1980
122
0.010
 Why?
Lung
1
1992
4108
0.010
 Why?
Personnel Selection
1
1980
93
0.010
 Why?
Interleukin-4
1
1999
206
0.010
 Why?
Thalassemia
1
1998
6
0.010
 Why?
Receptors, Purinergic P1
1
1998
30
0.010
 Why?
Heart Failure
1
1992
2314
0.010
 Why?
Microscopy, Fluorescence
1
2000
416
0.010
 Why?
Reference Values
1
2000
797
0.010
 Why?
Multicenter Studies as Topic
1
2000
402
0.010
 Why?
Acute Disease
1
2001
1028
0.010
 Why?
Pilot Projects
2
1994
1867
0.010
 Why?
Infant, Newborn
1
2009
6424
0.010
 Why?
Filgrastim
1
1997
13
0.010
 Why?
Killer Cells, Natural
1
2000
467
0.010
 Why?
Adenoviruses, Human
1
1996
26
0.010
 Why?
Heparin
1
1998
243
0.010
 Why?
Lymphoma, B-Cell
1
1998
132
0.010
 Why?
Tissue Plasminogen Activator
1
1998
244
0.010
 Why?
Freezing
1
1996
85
0.010
 Why?
Lymphocyte Activation
1
2000
1126
0.010
 Why?
Pregnancy
1
2009
7180
0.010
 Why?
Lymphocyte Depletion
1
1996
132
0.010
 Why?
Genes, Reporter
1
1996
275
0.010
 Why?
Carcinoma, Squamous Cell
1
2001
641
0.010
 Why?
Drug Tolerance
1
1995
100
0.010
 Why?
Reticulocyte Count
1
1994
7
0.010
 Why?
Kidney Function Tests
1
1995
157
0.010
 Why?
Topotecan
1
1994
17
0.010
 Why?
Incidence
1
2001
2870
0.010
 Why?
Liver
1
2002
1884
0.010
 Why?
Antigens, CD
1
1996
555
0.010
 Why?
Urinary Bladder Diseases
1
1993
18
0.010
 Why?
Glioblastoma
1
1996
353
0.010
 Why?
Heart
1
1997
633
0.010
 Why?
Boston
1
1993
92
0.010
 Why?
Registries
1
2002
2382
0.010
 Why?
Flow Cytometry
1
1996
1172
0.010
 Why?
Chromatography, High Pressure Liquid
1
1995
593
0.010
 Why?
Iron
1
1994
359
0.010
 Why?
Cell Line
1
1996
2879
0.010
 Why?
Immunologic Factors
1
1993
255
0.010
 Why?
Cystitis
1
1990
23
0.000
 Why?
Palliative Care
1
1998
996
0.000
 Why?
Prostatic Neoplasms
1
1996
974
0.000
 Why?
Metabolic Clearance Rate
1
1989
114
0.000
 Why?
Introns
1
1990
254
0.000
 Why?
Platinum
1
1989
50
0.000
 Why?
Brain Diseases
1
1990
152
0.000
 Why?
Macrophage-1 Antigen
1
1988
26
0.000
 Why?
Bone Marrow Examination
1
1988
4
0.000
 Why?
Drug Combinations
1
1990
390
0.000
 Why?
Erythrocyte Count
1
1988
21
0.000
 Why?
Platelet Count
1
1988
96
0.000
 Why?
Methods
1
1988
69
0.000
 Why?
Pelvic Neoplasms
1
1988
24
0.000
 Why?
Erythroblasts
1
1988
19
0.000
 Why?
Infant
1
2002
10022
0.000
 Why?
DNA Damage
1
1990
428
0.000
 Why?
Acute Kidney Injury
1
1995
862
0.000
 Why?
In Vitro Techniques
1
1988
1047
0.000
 Why?
Fever
1
1988
311
0.000
 Why?
Pneumonia
1
1992
630
0.000
 Why?
Statistics as Topic
1
1987
281
0.000
 Why?
Elias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (665) concept(s)
_
Co-Authors Expand Description
See all (59) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)